Profit forecasting and investment advice

The company is actively deploying the medical and “Internet +” fields, and strategic transformation continues to advance. The company's net profit for 17-19 is expected to be 107 million yuan, 141 million yuan, and 169 million yuan. The corresponding EPS is 0.18 yuan, 0.24 yuan, and 0.29 yuan respectively. Since the company's business expansion is still in the adjustment stage, short-term profits have not yet been released. It was given 70 times PE for 18 years, with a corresponding target price of 16.8 yuan, and a “increase in holdings” rating.

Risk warning

The subsidiary's business fell short of expectations.

Prices of raw materials are rising.

The development of e-commerce platforms fell short of expectations.

Environmental policies are becoming stricter